10-Q: Ascend Wellness Reports Q2 Revenue Dip, Margin Gains

Ascend Wellness Holdings, Inc. reported a 10% revenue decrease for Q2 2025, alongside improved gross and Adjusted EBITDA margins, and a higher net loss.

Summary

• Revenue for the three months ended June 30, 2025, decreased by $14.23 million, or 10%, to $127.30 million compared to $141.54 million in the prior year period.
• Net loss for Q2 2025 increased to $(24.41) million from $(21.78) million in Q2 2024.
• Gross profit margin improved to 32.5% in Q2 2025 from 29.4% in Q2 2024, driven by improved realization at cultivation facilities and higher volume of company-produced products sold.
• Operating loss improved by 34% to $(1.00) million in Q2 2025 from $(1.52) million in Q2 2024, primarily due to improved margins and reduced general and administrative expenses.
• Adjusted EBITDA for Q2 2025 was $28.56 million, a slight increase from $28.35 million in Q2 2024, with Adjusted EBITDA Margin improving to 22.4% from 20.0%.
• Cash and cash equivalents increased by $7.02 million year-to-date, ending the period at $95.27 million, primarily driven by positive net cash from operating activities.
• Total debt increased to $370.01 million as of June 30, 2025, from $329.33 million at December 31, 2024, largely due to new term notes.
• The company prepaid the remaining $60.00 million outstanding under its previous credit facility in May 2025, utilizing $10.00 million cash on hand and $50.00 million from new term loans.
• As of June 30, 2025, the company operates 44 retail locations, including 6 partner locations, and aims for a medium-term target of 60 total retail locations.
• The company sold approximately 56,000 pounds of wholesale product (gross basis) in Q2 2025, up from 47,000 pounds in Q2 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company demonstrated improved operational efficiency through higher gross and Adjusted EBITDA margins and reduced operating loss, the significant revenue decline and increased net loss are concerning. The substantial increase in debt and the ongoing 'going concern' disclosure, despite management's reassurance, indicate financial pressures. The active expansion and acquisition strategy, while positive for future growth, also introduces execution and regulatory risks, especially with multiple pending approvals.

Positives

• Gross profit margin improved to 32.5% in Q2 2025 from 29.4% in Q2 2024, indicating better operational efficiency in production and sales.
• Operating loss significantly improved by 34% to $(1.00) million in Q2 2025, reflecting effective cost-savings initiatives and reduced general and administrative expenses.
• Adjusted EBITDA increased slightly to $28.56 million in Q2 2025, with Adjusted EBITDA Margin expanding to 22.4%, demonstrating stronger underlying profitability.
• Cash and cash equivalents increased by $7.02 million year-to-date to $95.27 million, supported by positive net cash provided by operating activities.
• Working capital improved significantly to $124.86 million as of June 30, 2025, from $84.84 million at December 31, 2024.
• The company successfully refinanced and terminated its previous credit facility by issuing new term notes, extending debt maturity to July 2029.
• Wholesale product volume increased to 56,000 pounds in Q2 2025 from 47,000 pounds in Q2 2024, indicating growth in production and distribution capacity.

Negatives

• Revenue decreased by 10% in Q2 2025, primarily due to increased competition and pricing pressure in key markets like Illinois and New Jersey.
• Net loss increased to $(24.41) million in Q2 2025 from $(21.78) million in Q2 2024, driven by higher interest expense.
• Interest expense increased by 41% to $(12.06) million in Q2 2025, largely due to higher weighted-average debt balances and interest rates (11.6% in Q2 2025 vs. 9.5% in Q2 2024).
• The company recorded $5.14 million in higher inventory write-downs in Q2 2025 related to net realizable value adjustments, expired products, and obsolete packaging.
• The accumulated deficit increased to $(444.02) million as of June 30, 2025, from $(400.36) million at December 31, 2024, and the company continues to report net losses.
• The company's financial statements include an indicator that raises substantial doubt about its ability to continue as a going concern, despite management's belief that it has been alleviated.

Risks

• Volatility of the market price and liquidity risks on Class A common stock.
• Voting control exercised by holders of Class B common stock.
• Ability to attract and maintain, and reliance on, key personnel.
• Ability to continue to open new dispensaries and cultivation facilities and grow as anticipated.
• Illegality of cannabis under federal law, posing ongoing legal and regulatory risks.
• Ability to comply with evolving state and federal regulations.
• Uncertainty regarding enforcement of cannabis laws in the U.S.
• Restricted access to banking and other financial services due to federal illegality of cannabis.
• Constraints on marketing and risks related to cannabis products.
• Unfavorable tax treatment for cannabis businesses under IRC Section 280E, limiting deductible expenses.
• Effect of proposed legislation on tax liabilities and financial performance.
• Security risks inherent in the cannabis industry.
• Infringement or misappropriation claims by third parties.
• Ability to comply with potential future U.S. Food and Drug Administration (FDA) regulations.
• Ability to enforce contracts in a federally illegal industry.
• Effect of unfavorable publicity or consumer perception.
• Risks related to material acquisitions, dispositions, and other strategic transactions.
• Agricultural and environmental risks affecting cultivation.
• Impacts of climate change.
• Risks related to information technology systems.
• Unknown health impacts associated with the use of cannabis and cannabis derivative products.
• Product liability claims and other litigation.
• Risks related to the results of future clinical research.
• Intense competition in the cannabis industry.
• Effect of the maturation of the cannabis market.
• Effect of adverse changes in wholesale and retail prices.
• Impact of sustained inflation.
• Political and economic instability.
• Effect of outbreaks of pandemic diseases or economic disturbances due to such outbreaks.
• General economic risks, such as unemployment level, interest rates, and inflation, and challenging global economic conditions.

Future Outlook

The company expects continued growth to be driven by opening new operational facilities and dispensaries under current licenses, expansion of existing facilities, and increased consumer demand. It plans to achieve a target of 60 total retail locations in the medium-term and is pursuing partnerships with social equity license holders. Management intends to access capital markets for additional funding through debt and/or equity financings to supplement future cash needs and fund growth initiatives. The company anticipates capital expenditures of approximately $30.0 million to $35.0 million for 2025, focusing on building out additional dispensaries and expanding cultivation facilities. The closing of several pending acquisitions is subject to regulatory approval, with some expected by the end of 2025 or within six to twelve months.

Management Comments

• The company continues to focus on expansion opportunities across the markets in which it operates and remains committed to cost-savings initiatives, improvements in working capital management, and providing an enhanced customer experience.
• Management believes that substantial doubt of our ability to continue as a going concern for at least one year from the issuance of our Financial Statements has been alleviated due to the cash balance on hand and the generation of positive net cash provided by operating activities.
• Management plans to continue to access capital markets for additional funding through debt and/or equity financings to supplement future cash needs, as may be required.
• However, management cannot provide any assurances that the Company will be successful in accomplishing its business plans.
• If we are unable to raise additional capital on favorable terms, if at all, whenever necessary, we may be forced to decelerate or curtail certain of our operations until such time as additional capital becomes available.

Industry Context

The company operates in the U.S. cannabis industry, which is characterized by its multi-state, vertically integrated nature and limited license markets. Despite state-level legalization, cannabis remains federally illegal, leading to unique challenges such as restricted access to banking services and unfavorable tax treatment under IRC Section 280E. The industry is experiencing increased competition and pricing pressure in various markets, particularly Illinois and New Jersey, impacting wholesale and retail revenues. The company's strategy of expanding its retail footprint and cultivation capacity, alongside pursuing social equity partnerships, aligns with broader industry trends of consolidation and market penetration in evolving regulatory landscapes.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or industry benchmarks to assess the results against global standards. However, the reported gross margin improvement to 32.5% in Q2 2025 (from 29.4% in Q2 2024) and Adjusted EBITDA margin improvement to 22.4% (from 20.0%) suggest operational efficiency gains despite a challenging market with increased competition and pricing pressure. These margin improvements are notable in an industry often facing high cost of goods sold due to cultivation and processing, and significant tax burdens under IRC Section 280E. The revenue decline, while concerning, is attributed to market-specific pressures rather than internal operational failures, which is a common theme among multi-state operators navigating maturing markets.

Corporate Governance

Legal Proceedings

• The company is engaged in litigation with subsidiaries of MedMen Enterprises Inc. (MedMen) regarding a definitive investment agreement for MedMen NY, Inc. (MMNY).
• The company is seeking damages from MedMen, including the return of a $4.00 million deposit, approximately $2.40 million in working capital advances, and other capital expenditure advances, totaling $10.30 million.
• MedMen filed for bankruptcy in Canada in April 2024 and was placed into receivership in California in April 2024, with reports indicating liabilities significantly exceed estimated liquidated asset values.
• The company filed a motion for a default judgment against MedMen on August 6, 2025, seeking $10.30 million.
• The company has established and increased an estimated reserve for these amounts, totaling $2.42 million in Notes receivable, $6.70 million in Other current assets, and the remainder in Other noncurrent assets as of June 30, 2025.

Related Party Transactions

• The Massachusetts Note, with $4.10 million outstanding as of June 30, 2025, was issued to a retail dispensary license holder partially owned by an entity managed by one of the company's founders. The company also transacts with this dispensary in the ordinary course of business.
• The company has entered into various loan agreements and management services agreements with Variable Interest Entities (VIEs) such as Core Partnership One, Core Partnership Two, Core Partnership Three, Core Partnership Four, and Non-Core Partnership One, which are consolidated due to the company's operational and financial influence and right to receive benefits. Intercompany activity related to these is eliminated in consolidation.

Stakeholder Impact

• **Shareholders**: Experience increased net losses and accumulated deficit, but also benefit from improved operating margins and a share buyback program. The increase in debt and the 'going concern' disclosure could be a concern, but management believes it's alleviated. Class B common stockholders retain significant voting control (1,000 votes per share).
• **Employees**: The company employs approximately 2,300 people and continues to expand operations, suggesting job stability and growth opportunities. Equity-based compensation plans are in place to incentivize employees.
• **Customers**: The company aims to provide safe, reliable, and high-quality products and expand its retail footprint (target 60 locations), potentially increasing access and options for consumers.
• **Suppliers/Creditors**: The company's increased debt load and reliance on future capital raises could impact creditors. However, improved working capital and positive operating cash flow provide some reassurance regarding short-term obligations. The company has commercial relationships with license holders for purchasing and supply arrangements.
• **Regulatory Authorities**: The company operates in a complex and evolving regulatory environment, with ongoing compliance requirements and potential for fines or restrictions. The federal illegality of cannabis remains a significant overarching factor.

Next Steps

• Continue focus on expansion opportunities across existing markets.
• Implement further cost-savings initiatives and improvements in working capital management.
• Enhance customer experience across retail operations.
• Open new operational facilities and dispensaries under current licenses.
• Expand current cultivation facilities.
• Pursue opportunities to partner with social equity license holders.
• Access capital markets for additional funding through debt and/or equity financings as needed.
• Finalize regulatory approvals and close pending acquisition transactions, including Core Partnership Dispensary Three, Core Partnership Dispensary Four, Non-Core Partnership Dispensary One, and various adult-use licenses.
• Complete anticipated capital expenditures of $30.0 million to $35.0 million for 2025, focusing on dispensary build-outs and cultivation facility expansions.
• Evaluate the impacts of the recently enacted 'One Big Beautiful Bill Act' on consolidated financial statements and disclosures.
• Continue to pursue collection of damages from MedMen in the ongoing litigation, including the motion for default judgment seeking $10.30 million.
• Exercise option to acquire Ohio Patient Access LLC (OPA) prior to the amended expiration date of March 22, 2026.

Key Dates

Recommendation

The company presents a mixed financial picture. While it achieved notable improvements in gross and Adjusted EBITDA margins and reduced its operating loss, the top-line revenue decline and increased net loss are significant concerns. The substantial increase in debt, though used for refinancing and growth, adds financial leverage. The 'going concern' disclosure, even if management believes it's alleviated, is a formal risk. The company is actively expanding its footprint and pursuing strategic acquisitions, which could drive future growth, but these are subject to regulatory delays and execution risks in a highly competitive and federally illegal industry. Given the operational improvements balanced against revenue contraction, increased debt, and inherent industry risks, a 'hold' recommendation is appropriate for investors seeking to monitor the company's ability to execute its expansion plans and navigate the challenging regulatory and competitive landscape.

Keywords

Cannabis, Multi-state operator, Marijuana, Dispensary, Cultivation, Adult-use cannabis, Medical cannabis, SEC filing, 10-Q, Financial results, Cannabis industry, AAWH, Ascend Wellness, Regulatory compliance, IRC Section 280E, Liquidity, Debt financing, Acquisitions, Retail expansion